21755-34-0

Basic information

• Product Name: Imidazo[1,2-a]pyridine-2-acetic acid ethyl ester
• Synonyms: Imidazo[1,2-a]pyridine-2-acetic acid ethyl ester;ethyl imidazo[1,2-a]pyridin-2-ylacetate;Minodronic Acid related substance;Minodronic acid InterMediate A isoMer;Minodronic Acid Related Compound;ethyl 2-(imidazo[1,2-a]pyridin-2-yl)acetate;Minodronic Impurity 1
• CAS NO: 21755-34-0
• Molecular Formula: C11H12N2O2
• Molecular Weight: 204.228
• Mol File: 21755-34-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 62 °C
• Boiling Point: 108-112 °C(Press: 1.3 Torr)
• Appearance: /
• Density: 1.19
• Refractive Index: 1.583
• PKA: 6.74±0.50(Predicted)
• CAS DataBase Reference: Imidazo[1,2-a]pyridine-2-acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyridine-2-acetic acid ethyl ester(21755-34-0)
• EPA Substance Registry System: Imidazo[1,2-a]pyridine-2-acetic acid ethyl ester(21755-34-0)

Safety Data

• Hazardous Substances Data: 21755-34-0(Hazardous Substances Data)

Usage

Uses

Imidazo[1,2-a]pyridine-2-acetic acid ethyl ester is a useful research chemical.

InChI:InChI=1/C11H12N2O2/c1-2-15-11(14)7-9-8-13-6-4-3-5-10(13)12-9/h3-6,8H,2,7H2,1H3

Upstream product

• 504-29-0 2-aminopyridine 
• 84911-18-2 ethyl 2-bromoacetoacetate 
• 13176-46-0 4-bromoethyl acetoacetate 
• 638-07-3 ethyl (2-chloroaceto)acetate 

Relevant articles and documents

In search of imidazo [1,2-a] pyridine derivatives exhibiting resistance for catalytic hydrogenation

Effect of substituents on the pyridine ring of imidazo [1,2-a] pyridine derivatives have been studied to ascertain the structural requirement for offering resistance towards catalytic hydrogenation of the title compounds.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders

Heterocyclic compounds having anti-diabetic activity and their use

Compounds of formula (I): STR1 [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5] have hypoglycemic and anti-diabetic activities.